SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ebola Outbreak 2014 - News, Updates and Related Investments
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: statesidereport7/31/2014 10:24:49 AM
   of 608
 
Looks like the CONX ebola rapid test is good to go. I wonder if they will fast track approvals? This is from the poster presented this week. Remember, it takes days to test for ebola now as it must be sent out to labs. The CONX test is done in 15 minutes.

This is an extract from Corgenix AACC poster from this week, confirming that all necessary antibodies for Ebola antigens are identified and the ELISA test in development is sensitive enough to be used in austere environments as point of care test
***********************************************
Results: As demonstrated by ELISA, we found polyclonal antibody pairings against
EBOV and SUDV VP40 to be the most reliable in detecting purifi ed recombinant
protein in spiked samples. Pairings exhibited limits of detection as low as 10ng/mL,
and limits of quantitation ranging from 10-100ng/mL, suggesting that these critical
reagents possess the ability to detect low amounts of EBOV and SUDV protein.
Pairings migrated to the LFI test strips showed the ability to detect both EBOV and
SUDV VP40 recombinant protein in a dose-dependent manner down to 100ng/mL
within 10 minutes. Importantly, this dose-dependency was distinguishable with the
naked eye, indicating the utility of this rapid test in environments lacking conditioned
power and/or signifi cant medical training.

Conclusions: We have developed and characterized prototype ELISA and LFI tests
capable of detecting EBOV and SUDV proteins in sample matrix. In the ELISA
format, multiple pairings were able to detect EBOV and SUDV VP40 antigens in
spiked matrix with acceptable sensitivity, suggesting that with further optimization
and ELISA test for the detection of EBOV and SUDV is within reach. In the LFI
platform, two pairings showed the ability to detect EBOV and SUDV antigens in
a concentration-dependent manner. Importantly, this concentration dependency was
discernible without the aid of any instrumentation, suggesting a path forward for the
optimization of a rapid, point-of-care test that can be used in austere environments.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News